TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Balaxi Pharma Ltd
BALAXI

Balaxi Pharma Ltd Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 34/100 · Weak See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹22.82

Change

+0.09 (0.4%)

Open

₹22.43

Prev. Close

₹22.73

Day High

₹23.28

Day Low

₹22.43

Volume Analysis

Traded

11,304

Delivered

8,191

Delivery %

72.46%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (4)

  • •Low return on equity (0.59%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (34/100)
  • •Low operating margin (3.2%)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹24.1 ₹23.69 ₹23.25 ₹22.84 ₹22.4 ₹21.99 ₹21.55
Fibonacci ₹23.69 ₹23.37 ₹23.16 ₹22.84 ₹22.52 ₹22.31 ₹21.99
Camarilla ₹23.05 ₹22.98 ₹22.9 ₹22.84 ₹22.74 ₹22.66 ₹22.59

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-19.34%

1 Week

-2.52%

1 Month

+1.24%

3 Months

-4.56%

6 Months

+21.38%

1 Year

-47.11%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹16.24

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

0.77%

Net margin 0.71% × asset turnover 0.8x × equity multiplier 1.35x

Company Overview

Sector

Healthcare

Market Cap

₹126 Cr

P/E (TTM)

52.0

ROE

0.59%

Book Value

₹45.1

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.

TopFund Analysis

Balaxi Pharma Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 34/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (0.59%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

34/100 — Weak

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

4

Valuation

12

Cash Flow

0

Corporate Governance

43

Momentum

26

Institutional Ownership

31

Business Quality

26

Risk & Volatility

56

Liquidity

50

From Screener.in

  • +Stock is trading at 0.49 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of 3.15% over past five years.
  • −Company has a low return on equity of -3.58% over last 3 years.
  • −Earnings include an other income of Rs.3.62 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Updates 07 Sep

RTA reported nil re-lodgement transfer requests for physical shares in August 2026.

General Updates 31 Aug

Balaxi receives WHO-GMP certification for Jadcherla facility; initial product manufacturing has commenced.

Change in Director(s) 24 Aug

Shareholders approved re-appointment of Ms. Akshita Ostwal as independent director for five years from September 5, 2026.

Shareholders meeting 24 Aug

83rd AGM held on 24 Aug 2026; shareholders approved audited statements and director reappointments.

Shareholders meeting 24 Aug

83rd AGM held on 24 Aug 2026; all four resolutions passed with requisite majority.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 66 55 61 60 66 77 73 76 71 56 73 71 81
Expenses + 57 44 47 46 56 67 69 64 67 55 69 71 76
Operating Profit 9 11 14 13 10 11 4 13 4 1 3 0 5
OPM % 13.4% 19.66% 22.45% 22.51% 15.38% 13.69% 5.44% 16.45% 5.88% 2.06% 4.26% 0.17% 5.78%
Other Income + -48 6 2 -1 -2 -4 4 -2 -2 2 0 3 -1
Interest 0 0 0 1 0 0 1 1 1 1 1 1 1
Depreciation 0 1 0 1 0 0 0 0 0 0 1 1 1
Profit before tax -39 16 14 11 7 6 6 10 1 1 2 1 2
Tax % 4.9% 7.92% 4.77% 4.87% 12.06% 17.41% 11.7% 10.56% 67.03% 84.06% 80.75% 56.43% 38.28%
Net Profit + -41 14 14 11 6 5 5 9 0 0 0 1 1
EPS in Rs -8 3 3 2 1 1 1 2 0 0 0 0 0
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 14 46 231 279 336 241 293 270 280
Expenses + 12 37 189 229 279 197 254 261 271
Operating Profit 2 8 43 51 57 45 38 10 9
OPM % 11.0% 18.0% 18.0% 18.0% 17.0% 18.0% 13.0% 3.5% 3.2%
Other Income + 1 1 2 5 3 -38 -4 3 4
Interest 0 0 0 1 1 3 4 5 4
Depreciation 0 0 0 1 2 2 2 2 3
Profit before tax 2 9 44 55 57 2 29 5 6
Tax % 19.0% 31.0% 14.0% 13.0% 19.0% 219.0% 13.0% 73.0% —
Net Profit + 2 6 38 48 46 -2 25 1 2
EPS in Rs 1 1 8 10 9 0 5 0 0
Dividend Payout % 0.0% 0.0% 0.0% 1.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 0 18 55 103 173 190 221 238
Borrowings + 0 0 4 4 13 19 53 58
Other Liabilities + 3 8 31 60 43 38 25 30
Total Liabilities 6 36 100 176 240 258 310 337
Fixed Assets + 0 0 2 29 41 41 41 82
CWIP 0 0 0 1 3 2 22 0
Investments 0 0 3 0 0 0 0 0
Other Assets + 6 36 94 147 195 215 247 255
Total Assets 6 36 100 176 240 258 310 337
Equity Capital 3 10 10 10 10 11 11 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -2 -14 0 34 6 5 -35 -4
Cash from Investing Activity + 0 0 -6 -28 -11 -1 -22 -21
Cash from Financing Activity + 0 18 4 0 26 30 34 0
Net Cash Flow -2 4 -2 6 21 34 -23 -25
CFO/OP -97 -161 6 78 32 26 -83 2
Free Cash Flow -2 -14 -3 7 -9 4 -57 -25

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 71.22% → 65.99%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 10.18% 10.18% 15.91% 17.11% 17.5% 17.5% 17.96% 25.12% 30.49% 32.24% 31.45% 31.45%
Promoters 71.22% 71.22% 66.86% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99%
FII 18.57% 18.57% 17.21% 16.88% 16.48% 16.48% 16.02% 8.87% 3.5% 1.74% 0.0% 0.0%
DII 0.03% 0.03% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 2.56% 2.56%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Balaxi Pharma Ltd (this stock) 126 52.0 0.51 0.59%
Alpa Laboratories Ltd 124 30.6 0.67 8.39%
Vaishali Pharma Limited 112 25.2 1.63 6.02%
Makers Laboratories Ltd. 107 31.4 1.48 3.17%
Parnax Lab Ltd. 149 14.8 1.56 14.4%
Sunil Healthcare Ltd. 78 21.1 1.12 6.01%
Bal Pharma Ltd. 175 24.4 2.13 7.87%

Which Mutual Funds Hold Balaxi Pharma Ltd?

Frequently Asked Questions about Balaxi Pharma Ltd

Community Sentiment

What are other investors saying about Balaxi Pharma Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.